Janssen Signs Results-Based Contract with Oklahoma Health Care Authority (OHCA) for its Long-Acting Injectable Schizophrenia Medicines
TITUSVILLE, N.J., Dec. 13, 2018 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today a results-based contract for long-acting injectable schizophrenia medicines (LAIs) with the Oklahoma Health Care Authority (OHCA), which manages Oklahoma's Medicaid plan, SoonerCare. The agreement was made between Janssen Pharmaceuticals, Inc. and OHCA.
Under this arrangement focused on enabling the use of INVEGA SUSTENNA® (paliperidone palmitate) and INVEGA TRINZA® (paliperidone palmitate) earlier in treatment of adults with schizophrenia, OHCA aims to improve care among patients with schizophrenia and reduce expenses for medical services. The agreement enables potential cost savings for OHCA for these medicines.
"Oklahoma is excited to work with a major manufacturer like Janssen," said Nancy Nesser, J.D., Pharm.D., OHCA Pharmacy Director. "INVEGA SUSTENNA® has been shown to delay time to relapse and hospitalization compared to a group of oral antipsychotics, providing a significant opportunity to curb medical costs. And this, along with improved health care, is our goal for SoonerCare members."
A comparative effectiveness study found that the long-acting treatment INVEGA SUSTENNA® demonstrated superiority versus a group of seven commonly prescribed oral treatments in delaying time to relapse. Additionally, the time to first psychiatric hospitalization or arrest and/or incarceration was significantly longer for people treated with INVEGA SUSTENNA® compared to those treated with commonly prescribed oral antipsychotics. The study was not powered to compare the efficacy of INVEGA SUSTENNA® with that of the individual commonly prescribed oral antipsychotics used in the study.
A retrospective Medicaid claims analysis showed that INVEGA SUSTENNA® can lead to cost offsets in Medicaid programs.i Analysis of multistate data from Medicaid programs shows INVEGA SUSTENNA® was associated with a 36 percent reduction (per patient per month) in risk for all-cause hospitalization when compared to oral antipsychotics over a 12-month period.
INVEGA TRINZA® is the first and only schizophrenia treatment that is administered only four times a year, after patients have been adequately treated with INVEGA SUSTENNA® for at least four months. In a clinical trial, the median time to relapse in the INVEGA TRINZA® arm could not be estimated due to low percentage (7.4 percent) of patients with relapse.
In June 2018, Oklahoma became the first state to apply for and win approval from its federal partner, the Centers for Medicare & Medicaid Services (CMS), to pursue Medicaid supplemental results-based agreements with pharmaceutical manufacturers.
"With health care costs a concern nationwide, we're excited to be working with Oklahoma to expand patient access to these transformational medicines that can play a role in making public programs more sustainable," said Blasine Penkowski, Chief Strategic Customer Officer, Johnson & Johnson Health Care Systems Inc. "We're pleased that Oklahoma sees their clinical and economic value and their potential to reduce costs by improving care for patients with schizophrenia."
The agreement reflects Janssen's commitment to moving to a results-based health care system that will help control cost while delivering better quality care.
More Information About INVEGA TRINZA® and INVEGA SUSTENNA®
INVEGA SUSTENNA® (paliperidone palmitate) was approved by the U.S. FDA in July 2009 as the first once-monthly, atypical, long-acting injection to treat schizophrenia and is now approved in more than 80 countries.
In May 2015, the U.S. FDA approved INVEGA TRINZA® (paliperidone palmitate), the first and only schizophrenia treatment to be administered four times a year.
INVEGA SUSTENNA® (In-VEY-guh Suss-TEN-uh) (paliperidone palmitate) is a prescription medicine given by injection by a healthcare professional. INVEGA SUSTENNA® is used to treat schizophrenia in adults.
IMPORTANT SAFETY INFORMATION
Do not receive INVEGA TRINZA® or INVEGA SUSTENNA® if you are allergic to paliperidone, paliperidone palmitate, risperidone, or any of the ingredients in INVEGA TRINZA® or INVEGA SUSTENNA®. See the end of the Patient Information leaflet in the full Prescribing Information for a complete list of INVEGA TRINZA® and INVEGA SUSTENNA® ingredients.
Before you receive INVEGA TRINZA® or INVEGA SUSTENNA®, tell your healthcare professional about all your medical conditions, including if you:
Tell your healthcare professional about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show to your healthcare professional or pharmacist when you get a new medicine.
Patients (particularly the elderly) taking antipsychotics with certain health conditions or those on long-term therapy should be evaluated by their healthcare professional for the potential risk of falls.
What should I avoid while receiving INVEGA TRINZA® or INVEGA SUSTENNA®?
INVEGA TRINZA® and INVEGA SUSTENNA® may cause serious side effects, including:
The most common side effects of INVEGA TRINZA® include: injection site reactions, weight gain, headache, upper respiratory tract infections, feeling restlessness or difficulty sitting still, slow movements, tremors, stiffness and shuffling walk.
The most common side effects of INVEGA SUSTENNA® include: injection site reactions; sleepiness or drowsiness; dizziness; feeling of inner restlessness or needing to be constantly moving; abnormal muscle movements, including tremor (shaking), shuffling, uncontrolled involuntary movements, and abnormal movements of your eyes.
Tell your healthcare professional if you have any side effect that bothers you or does not go away. These are not all the possible side effects of INVEGA TRINZA® or INVEGA SUSTENNA®. For more information, ask your healthcare professional or pharmacist.
Call your healthcare professional for medical advice about side effects. You may report side effects of prescription drugs to the FDA at 1-800-FDA-1088.
General information about the safe and effective use of INVEGA TRINZA® or INVEGA SUSTENNA®
This Patient Information leaflet summarizes the most important information about INVEGA TRINZA® and INVEGA SUSTENNA®. If you would like more information, talk with your healthcare professional.
You can ask your healthcare professional or pharmacist for more information that is written for healthcare professionals. For more information, go to www.invegatrinza.com or www.invegasustenna.com or call 1-800-526-7736.
Please see the full Prescribing Information, including Boxed WARNING, for INVEGA TRINZA® available here and INVEGA SUSTENNA® available here, and discuss any questions you have with your healthcare professional.
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science.
Janssen Pharmaceuticals, Inc., is part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Janssen Pharmaceuticals, Inc., markets INVEGA SUSTENNA® and INVEGA TRINZA® in the United States.
i Pesa JA, Muser E, Montejano LB, et al. Costs and resource utilization among Medicaid patients with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics. Drugs Real World Outcomes. 2015;2(4):377-385.
View original content:http://www.prnewswire.com/news-releases/janssen-signs-results-based-contract-with-oklahoma-health-care-authority-ohca-for-its-long-acting-injectable-schizophrenia-medicines-300765003.html
SOURCE Janssen Pharmaceutical Companies of Johnson & Johnson